A Phase 1, Double-blind, Randomized, Placebo-controlled, Multiple Ascending Dose Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TD−1439 in Healthy Subjects

Trial Profile

A Phase 1, Double-blind, Randomized, Placebo-controlled, Multiple Ascending Dose Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TD−1439 in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 31 Aug 2017

At a glance

  • Drugs TD 1439 (Primary)
  • Indications Cardiovascular disorders; Kidney disorders
  • Focus Adverse reactions
  • Sponsors Theravance Biopharma
  • Most Recent Events

    • 25 Aug 2017 Status changed from active, no longer recruiting to completed.
    • 30 Mar 2017 Status changed from recruiting to active, no longer recruiting.
    • 27 Feb 2017 According to a Theravance Biopharma media release, expected completion of this trial in 1H 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top